Myeloproliferative Neoplasms

Expert faculty review and share their insights on key findings in myelodysplastic neoplasms presented at the 2023 ASH Annual Meeting.

Share

Program Content

Activities

  • MPN Updates 2023
    Conference to Clinic: Myeloproliferative Neoplasm Updates 2023
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 11, 2024

  • ASH 2023: MPNs
    Key Studies in Myeloproliferative Neoplasms: Independent Conference Coverage of ASH 2023
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 06, 2024

    Expires: March 05, 2025

Activities

TRANSFORM 1
TRANSFORM-1: Phase III Trial of Navitoclax + Ruxolitinib vs Placebo + Ruxolitinib in Previously Untreated Myelofibrosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

RuxoBEAT
RuxoBEAT: Interim Results From a Randomized Phase IIb Study of Ruxolitinib Vs BAT as First-line Therapy in High-Risk Polycythemia Vera
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

Bomedemstat in ET
Phase IIb Trial of LSD1 Inhibitor Bomedemstat in Patients With Essential Thrombocythemia Resistant or Intolerant to Standard Therapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

MANIFEST 2
MANIFEST-2: Phase III Trial of Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib for JAK Inhibitor–Naive Myelofibrosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

Bomedemstat Plus Ruxolitinib for MF
Phase II Study of Bomedemstat Plus Ruxolitinib for Patients With Myelofibrosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.